WGO Graded Evidence: Osteoporosis

Level: Other Reading: 36 Abstracts

Legend:   : Special Mention  : Important  : Very Important  : Key Development
	The effect of proton pump-inhibiting drugs on mineral metabolism. Insogna KL, Am J Gastroenterol. 2009 Mar;104(2 Suppl):S2-4
	Risk factors for low bone mass in patients with ulcerative colitis following ileal pouch-anal anastomosis. Shen B, Remzi FH, Oikonomou IK, Lu H, Lashner BA, Hammel JP, Skugor M, Bennett AE, Brzezinski A, Queener E, Fazio VW, Am J Gastroenterol. 2009 Mar;104(3):639-46
	Clinical practice. Glucocorticoid-induced bone disease. Weinstein RS., N Engl J Med. 2011 Jul 7;365(1):62-70.
	Gut, inflammation and osteoporosis: basic and clinical concepts. Tilg H, Moschen AR, Kaser A, Pines A, Dotan I, Gut. 2008 May;57(5):684-94
	Prevention and treatment of osteoporosis in inflammatory bowel disease. GR Lichtenstein, BE Sands, M Pazianas, Inflamm Bowel Dis. 2006 Aug:797-813
	Bisphosphonates for osteoporosis. Favus MJ., N Engl J Med. 2010 Nov 18;363(21):2027-35.
	Bones in pediatric Crohn's disease: A review of fracture risk in children andadults. Hill RJ, Brookes DS, Davies PS., Inflamm Bowel Dis. 2010 Sep 7. [Epub ahead of print]
	Lasofoxifene in postmenopausal women with osteoporosis. Cummings SR, Ensrud K, Delmas PD, LaCroix AZ, Vukicevic S, Reid DM, Goldstein S, Sriram U, Lee A, Thompson J, Armstrong RA, Thompson DD, Powles T, Zanchetta J,Kendler D, Neven P, Eastell R; PEARL Study Investigators., N Engl J Med. 2010 Feb 25;362(8):686-96.
	Analysis of risk factors for low bone mineral density in inflammatory bowel disease. P Frei, M Fried, V Hungerbuhler, C Rammert, V Rousson, GA Kullak-Ublick, Digestion. 2006:40-6
	Do guidelines matter? Implementation of the ACG and AGA osteoporosis screening guidelines in inflammatory bowel disease (IBD) patients who meet the guidelines' criteria. A Kornbluth, M Hayes, S Feldman, M Hunt, E Fried-Boxt, S Lichtiger, P Legnani, J George, J Young, Am J Gastroenterol. 2006 Jul:1546-50
	Guidelines do help change behavior in the management of osteoporosis by gastroenterologists. S Kane, D Reddy, Am J Gastroenterol. 2006 Aug:1841-4
	Intravenous pamidronate in combination with calcium and vitamin D: highly effective in the treatment of low bone mineral density in inflammatory bowel disease. PC Stokkers, M Deley, M Van Der Spek, HJ Verberne, SJ Van Deventer, DW Hommes, Scand J Gastroenterol. 2006 Feb:200-4
	Osteoporosis in pediatric patients suffering from chronic inflammatory bowel disease with and without steroid treatment. F Walther, C Fusch, M Radke, S Beckert, A Findeisen, J Pediatr Gastroenterol Nutr. 2006 Jul:42-51
	Interpretation and use of FRAX in clinical practice. Kanis JA, Hans D, Cooper C, Baim S, Bilezikian JP, Binkley N, Cauley JA, CompstonJE, Dawson-Hughes B, El-Hajj Fuleihan G, Johansson H, Leslie WD, Lewiecki EM,Luckey M, Oden A, Papapoulos SE, Poiana C, Rizzoli R, Wahl DA, McCloskey EV; TaskForce of the FRAX Initiative., Osteoporos Int. 2011 Sep;22(9):2395-411. Epub 2011 Jul 21.
	Optimising bisphosphonate treatment outcomes in postmenopausal osteoporosis:review and Italian experience. Rossini M, Di Munno O, Gatti D, Giannini S, Minisola S, Varenna M, Adami S., Clin Exp Rheumatol. 2011 Jul-Aug;29(4):728-35. Epub 2011 Sep 1.
	Allergy and the bone: unexpected relationships. Gatti D, Senna G, Viapiana O, Rossini M, Passalacqua G, Adami S., Ann Allergy Asthma Immunol. 2011 Sep;107(3):202-6. Epub 2011 May 19.
	Osteoarthritis: an update with relevance for clinical practice. Bijlsma JW, Berenbaum F, Lafeber FP., Lancet. 2011 Jun 18;377(9783):2115-26.
	Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR, JAMA. 2009 Feb 4;301(5):513-21
	Bone quantitative ultrasound and bone mineral density in children with celiac disease. C Hartman, B Hino, A Lerner, O Eshach-Adiv, D Berkowitz, R Shaoul, A Pacht, E Rozenthal, A Tamir, H Shamaly, R Shamir, J Pediatr Gastroenterol Nutr. 2004 Nov:504-10
	The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. AR Moschen, A Kaser, B Enrich, O Ludwiczek, M Gabriel, P Obrist, AM Wolf, H Tilg, Gut. 2005 Apr:479-87
Supplementary evidence:
	A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis. G Pillai, R Gieschke, T Goggin, P Jacqmin, RC Schimmer, JL Steimer, Br J Clin Pharmacol. 2004 Dec:618-31
	Bone mineral assessment by dual energy X-ray absorptiometry in children with inflammatory bowel disease: evaluation by age or bone area. SF Ahmed, IA Horrocks, T Patterson, S Zaidi, SC Ling, P McGrogan, LT Weaver, J Pediatr Gastroenterol Nutr. 2004 Mar:276-80
	Bones and Crohn's: risk factors associated with low bone mineral density in patients with Crohn's disease. JS Siffiledeen, RN Fedorak, K Siminoski, H Jen, E Vaudan, N Abraham, H Seinhart, G Greenberg, Inflamm Bowel Dis. 2004 May:220-8
	Case-finding for adult celiac disease in patients with reduced bone mineral density. DS Sanders, D Patel, FB Khan, RH Westbrook, CV Webber, A Milford-Ward, EV McCloskey, Dig Dis Sci. 2005 Mar:587-92
	Celiac disease in patients with an affected member, type 1 diabetes, iron-deficiency, or osteoporosis? JA Murray, Gastroenterology. 2005 Apr:S52-6
	Effect of antitumour necrosis factor-alpha therapy on bone turnover in patients with active Crohn's disease: a prospective study. BM Ryan, MG Russel, L Schurgers, M Wichers, J Sijbrandij, RW Stockbrugger, E Schoon, Aliment Pharmacol Ther. 2004 Oct 15:851-7
	Fracture risk of women with primary biliary cirrhosis: no increase compared with general population controls. JR Boulton-Jones, RM Fenn, J West, RF Logan, SD Ryder, Aliment Pharmacol Ther. 2004 Sep 1:551-7
	Gene polymorphisms as predictors of decreased bone mineral density and osteoporosis in primary biliary cirrhosis. A Parés, N Guañabens, J Rodés, Eur J Gastroenterol Hepatol. 2005 Mar:311-5
	Prevalence of Helicobacter pylori infection in male patients with osteoporosis and controls. N Figura, L Gennari, D Merlotti, C Lenzi, S Campagna, B Franci, B Lucani, L Trabalzini, L Bianciardi, C Gonnelli, A Santucci, A Nut, Dig Dis Sci. 2005 May:847-52
	Rapid hip bone loss in active Crohn's disease patients receiving short-term corticosteroid therapy. JH Tobias, MR Sasi, R Greenwood, CS Probert, Aliment Pharmacol Ther. 2004 Nov 1:951-7
	Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease. N Franchimont, V Putzeys, J Collette, S Vermeire, P Rutgeerts, M De Vos, A Van Gossum, D Franchimont, R Fiasse, P Pelckmans, M Malaise, J Belaiche, E Louis, Aliment Pharmacol Ther. 2004 Sep 15:607-14
	Review article: Osteoporosis and inflammatory bowel disease. CN Bernstein, WD Leslie, Aliment Pharmacol Ther. 2004 May 1:941-52
	Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis. N Guañabens, A Parés, I Ros, L Caballería, F Pons, S Vidal, A Monegal, P Peris, J Rodés, J Hepatol. 2005 Apr:573-7
	Vitamin A intake and osteoporosis: a clinical review. C Crandall, J Womens Health (Larchmt). 2004 Oct:939-53
	Vitamin K status in patients with Crohn's disease and relationship to bone turnover. P Duggan, M O'Brien, M Kiely, J McCarthy, F Shanahan, KD Cashman, Am J Gastroenterol. 2004 Nov:2178-85
	Which is the better choice, estrogen or SERMs in postmenopausal women? M Shintani, Clin Calcium. 2004 Oct:105-10